Victory Capital Management
CUE icon

Victory Capital Management’s Cue Biopharma CUE Stock Holding History

Victory Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-144
Closed -$61K – 2695
2020
Q1 		$61K Buy
+144
New +$69.8K ﹤0.01% 2468
2019
Q4 		– Sell
-116
Closed -$29K – 2787
2019
Q3 		$29K Buy
+116
New +$27.9K ﹤0.01% 2911

Other funds holding CUE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Victory Capital Management's CUE Position: Q2 2020 in Review

Victory Capital Management sold out of Cue Biopharma (CUE) in Q2 2020, closing a stake of 144 shares — an estimated $61K sold.

Victory Capital Management first reported a position in CUE in Q3 2019 and held it in 2 quarters. The position peaked at $61K in Q1 2020. 99 funds tracked by Wall St. Rank hold CUE as of Q2 2020.

  • Victory Capital Management reported no remaining Cue Biopharma position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 144 Cue Biopharma shares in Q2 2020, an estimated $61K.
  • Victory Capital Management first reported a position in Cue Biopharma in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Cue Biopharma position peaked at $61K in Q1 2020.
  • 99 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.